A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
| Autor: | Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., Gautschi, O., Nadal, E., Janthur, W.D., López Castro, R., García Campelo, R., Rusakiewicz, S., Letovanec, I., Polydoropoulou, V., Roschitzki-Voser, H., Ruepp, B., Gasca-Ruchti, A., Peters, S., Stahel, R.A. |
|---|---|
| Zdroj: | In Annals of Oncology December 2020 31(12):1734-1745 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|